Peer-reviewed veterinary case report
Variability of heart troponin levels in healthy dogs and dogs
By Winter, Randolph L et al.·Published in Veterinary clinical pathology·2017·Department of Small Animal Clinical Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Biologic variability of cardiac troponin I in healthy dogs and dogs with different stages of myxomatous mitral valve disease using standard and high-sensitivity immunoassays.
- Species:
- dog
Plain-English summary
A group of healthy dogs and dogs with different stages of myxomatous mitral valve disease (a heart condition) had their cardiac troponin I (cTnI) levels tested to understand how these levels vary. The study found that most healthy dogs had low cTnI levels, while dogs with heart disease showed more variability in their results. This means that when monitoring heart health in dogs, especially those with mitral valve disease, it's important to consider these variations in cTnI levels. The findings suggest that using high-sensitivity tests may help veterinarians better track changes in heart health over time.
People also search for: dog heart disease symptoms · myxomatous mitral valve disease in dogs · cardiac troponin I test for dogs
Abstract
BACKGROUND: Biologic variability (BV) is one aspect of interpreting changes in biomarker concentrations known to be clinically important in people with cardiac disease, but it has not been adequately addressed in dogs so far. OBJECTIVES: The purpose of the study was to determine BV of cardiac troponin I (cTnI) in healthy dogs and dogs with 3 stages of myxomatous mitral valve disease (MMVD). METHODS: Healthy dogs and dogs with 3 stages of MMVD were prospectively assigned to groups based on comprehensive clinical evaluation using current guidelines. Concentrations of cTnI were measured hourly, daily, and weekly using standard and high-sensitivity immunoassays. Within- (CV) and between-subject (CV) coefficients of variability, percent reference change value (RCV), and index of individuality (IoI) were calculated. RESULTS: All 10 healthy dogs and 76/112 (68%) of samples from 28 MMVD dogs had cTnI concentrations below the limit of detection (LOD) using a standard sensitivity immunoassay. Only 49/160 (31%) of healthy dog samples and no MMVD samples had cTnI below the high-sensitivity immunoassay LOD. Data analysis for the high-sensitivity immunoassay revealed CVof 48.1%, CVof 60.1%, RCV of 134.0%, and IoI of 0.804 in healthy dogs. In MMVD dogs, CVwas 39.6%, CVwas 80.7%, RCV was 110%, and IoI was 0.494. Of all MMVD dogs, those with Stage B2 had the lowest RCV of 91%. CONCLUSIONS: Biologic variability affects cTnI concentrations in healthy dogs and dogs with MMVD. Consideration of BV may be clinically relevant when monitoring individual changes in cTnI values, using high-sensitivity immunoassays.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/28449360/